StreetInsider.com News Articles

Form 424B3 YD Bio Ltd

Tue, 11 Aug 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260811/26905178.html

Form 6-K YD Bio Ltd For: Aug 11

Tue, 11 Aug 2026 15:22:00 -0400

si-local-file:///var/storage/secattach/20260811/26905172.html

YD Bio launches two nutraceutical products in Taiwan with physicians

Tue, 11 Aug 2026 08:03:12 -0400

YD Bio Limited (Nasdaq: YDES) announced the launch of two nutraceutical products in Taiwan, developed in collaboration with the Taiwan Chronic Disease Healthcare Association (CDHA) and the Future Health Institute (FHI), a physician-led health platform with more than 233,000 YouTube subscribers.

The two products are based on a chrono-nutrition concept: a daytime lipid-soluble formulation containing omega-3, vitamin D3, and vitamin K2, referred to as a "Golden Triangle" formula, and a nighttime zinc-plus-calcium formulation. Both products carry the Taiwan CDHA certification mark and a recommendation from FHI.

According to the company, the physician-partnership model is structured so that practicing clinicians define formulation requirements

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future

Tue, 11 Aug 2026 08:00:00 -0400

Two chrono-nutrition formulations — a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to expand this approach by exploring additional opportunities for collaboration with other physicians and healthcare organizations.

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its initial step towards building a physician-partnership ecosystem and related consumer health commercialization capabilities in Taiwan with the

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future

Tue, 11 Aug 2026 08:00:00 -0400

YD Bio publishes keratoconus computational research in Bioengineering

Tue, 04 Aug 2026 08:04:56 -0400

YD Bio Limited (Nasdaq: YDES) announced the publication of a peer-reviewed study in the journal Bioengineering examining potential stem-cell-based regenerative targets for keratoconus, a corneal disorder and a leading cause of corneal transplantation in young adults.

The study, co-authored by YD Bio scientists alongside researchers from Taipei Medical University and Taipei Medical University Hospital, introduces a computational framework that analyzes publicly available gene and protein databases to identify molecular candidates that could guide future therapeutic development.

Central to the research is a newly developed metric called the Cargo Prioritization Score, which ranks candidate molecules for potential use in stem-cell-derived exosome therapies. The

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

Tue, 04 Aug 2026 08:00:00 -0400

Published in Bioengineering, a collaborative study with Taipei Medical University researchers identifies key molecular candidates to help guide the development of regenerative therapies for corneal disease.

TAIPEI, Taiwan, Aug. 04, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today highlighted the publication of a new peer-reviewed study in the journal Bioengineering, published by Multidisciplinary Digital Publishing Institute. Co-authored by YD Bio scientists and physician-researchers from Taipei Medical University (“TMU”) and Taipei Medical University Hospital (“TMUH”), the study explores

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

Tue, 04 Aug 2026 08:00:00 -0400

YD Bio starts six-month cancer test pilot in British Columbia

Tue, 28 Jul 2026 08:03:19 -0400

YD Bio Limited (NASDAQ: YDES) announced the launch of a six-month pilot collaboration with Numia Health Inc., a British Columbia-based healthcare services provider, to establish a cross-border clinical workflow for physician-ordered, blood-based cancer testing for eligible patients in British Columbia, Canada.

According to a press release, the pilot is governed by a Pilot Service Agreement dated July 23, 2026, and involves YD Bio, its U.S. subsidiary YD Bio US Inc., and its affiliate EG BioMed US Inc. The pilot is initially limited to up to 50 patient episodes in the Lower Mainland region of British Columbia.

The OkaiDx blood-based laboratory-developed tests (LDTs)

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

Tue, 28 Jul 2026 08:00:00 -0400

The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada

Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the launch of a six-month pilot collaboration (the “Pilot”) pursuant to that certain Pilot Service Agreement, dated as of July 23, 2026 (the “Agreement”), by and among YD Bio, YD Bio US Inc., a subsidiary of YD Bio (“YD Bio US”), EG BioMed

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

Tue, 28 Jul 2026 08:00:00 -0400

The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Thu, 23 Jul 2026 08:00:00 -0400

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio’s and its affiliate EG BioMed Co., Ltd.’s (“EG BioMed”) participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026. The companies showcased their advancements and offerings across: ophthalmic regenerative medicine, DNA-based cancer detection, and U.S. market entry services for life science partners.

Advancements in Ophthalmology: Commercial

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Thu, 23 Jul 2026 08:00:00 -0400

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio’s and its affiliate EG BioMed Co., Ltd.’s (“EG BioMed”) participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026. The companies showcased their advancements and offerings across: ophthalmic regenerative medicine, DNA-based cancer detection, and U.S. market entry services for life science partners.

Advancements in Ophthalmology: Commercial

YD Bio lab gains licenses in Rhode Island and Pennsylvania

Thu, 02 Jul 2026 08:00:12 -0400

YD Bio Limited (Nasdaq: YDES) announced that its affiliate, EG BioMed US Inc., has obtained clinical laboratory licenses in Rhode Island and Pennsylvania, expanding the authorized operating footprint of its CLIA-certified, CAP-accredited laboratory in Bothell, Washington, to 46 U.S. states, plus Washington, D.C. and Guam.

The Rhode Island license, issued May 13, 2026, covers the clinical genetics specialty. The Pennsylvania permit, issued June 9, 2026, covers clinical chemistry and hematology. The company described both states as among the most tightly regulated in the United States.

The Bothell laboratory supports blood-based testing services for pancreatic, colorectal, breast, liver, and other gastrointestinal cancers using

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Thu, 02 Jul 2026 08:00:00 -0400

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation (“EG BioMed US”), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company’s transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.

The Rhode Island license, issued May 13, 2026, covers

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Thu, 02 Jul 2026 08:00:00 -0400

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation (“EG BioMed US”), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company’s transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.

The Rhode Island license, issued May 13, 2026, covers

Form 4 YD Bio Ltd For: Jun 30 Filed by: Chang Kochi

Wed, 01 Jul 2026 15:33:00 -0400
si-local-file:///var/storage/secattach/20260701/26720226.html

Form 4 YD Bio Ltd For: Jun 30 Filed by: Lu Shao-Ta

Wed, 01 Jul 2026 15:33:00 -0400
si-local-file:///var/storage/secattach/20260701/26720228.html

Form EFFECT YD Bio Ltd

Mon, 01 Jun 2026 06:07:00 -0400
si-local-file:///var/storage/secattach/20260601/26578481.html

Form POS AM YD Bio Ltd

Tue, 26 May 2026 17:18:00 -0400
si-local-file:///var/storage/secattach/20260526/26551292.html

Form 6-K YD Bio Ltd For: Apr 30

Fri, 01 May 2026 09:47:00 -0400
si-local-file:///var/storage/secattach/20260501/26413826.html

YD Bio Limited Reports Full Year 2025 Financial Results

Thu, 30 Apr 2026 18:00:00 -0400

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025.

Management Commentary
“2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our

YD Bio Limited Reports Full Year 2025 Financial Results

Thu, 30 Apr 2026 18:00:00 -0400

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025.

Management Commentary
“2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our

Form 20-F YD Bio Ltd For: Dec 31

Thu, 30 Apr 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260430/26408922.html

Form 3/A YD Bio Ltd For: Mar 18 Filed by: Lu Shao-Ta

Mon, 20 Apr 2026 11:47:00 -0400
si-local-file:///var/storage/secattach/20260420/26335741.html